SynthesisFrontiers in medicine2026
Contemporary management of treatment-related dermatologic toxicities in gynecologic cancers: a systematic review based on evidence from 2021 to 2025.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gynecologic cancers are commonly managed with chemotherapy, radiotherapy, and targeted therapies, which are effective but frequently associated with significant skin side effects. These dermatologic toxicities substantially reduce patients' quality of life and treatment adherence, highlighting the need for a comprehensive synthesis of the latest evidence to address this clinical challenge. Methods: This systematic review summarizes the most up-to-date evidence (as of 2025) regarding treatment-induced skin damage in patients with gynecologic cancers. It focuses on synthesizing data related to the clinical manifestations, subclinical changes, risk factors, and management strategies of these skin toxicities. Results: Key findings include three critical areas of focus: subclinical skin damage (early, mostly asymptomatic changes induced by medications such as paclitaxel), radiotherapy-related skin issues, and severe skin effects associated with novel targeted therapies. Additionally, innovative technologies (e.g., 3D printed radiotherapy devices) were identified as potential tools for preventing and mitigating dermatologic toxicities. Discussion: The review emphasizes the importance of individualized intervention plans and multidisciplinary care models to effectively manage treatment-related skin toxicities. By synthesizing the latest evidence on manifestations, mechanisms, risk factors, and innovative mitigation strategies, this review aims to provide clinicians with optimal information to improve outcomes for gynecologic cancer patients experiencing skin toxicities, thereby enhancing treatment adherence and overall patient well-being.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.